Background: High out of pocket expenses have led to poor diabetes self-management and glycemic control in India. This study evaluates the impact of an iPDM (integrated personalized diabetes management) on blood glucose (BG) control. Methods: Study participants (n=286) used an iPDM consisting of the Accu-Chek® Active BG meter and the Wellthy Care™ digital therapeutic platform (WDTx), which allowed them to log BG values while receiving artificial intelligence-powered real-time feedback and self-management education. The BG values at baseline (M0), month 2 (M2), month 4 (M4), and month 6 (M6) were analyzed. Mean BG (MBG), Fasting BG (FBG), Post-meal BG (PBG), number of hypoglycemia logs (<70 mg/dl), and in-range logs (FBG: 70-130 mg/dl; MBG/PBG: 70-180 mg/dl) were evaluated. Results: The average number of active days and BG logs by the participants was 75.9 days (95% CI: 66.0-85.7 days) and 73 logs (95% CI: 67-79 logs), respectively. The BG values and logs are summarized in Table 1. There was a significant reduction in BG from M0 to M2 after which the BG was stable over M4 and M6. There was also a reduction in the number of hypoglycemia logs and a corresponding increase in the number of in-range BG logs from M0 through M6. Conclusion: This study shows that an iPDM using SMBG and WDTx can be an effective and affordable tool for improving glycemic control and reducing hypoglycemia events in resource limited countries like India. Disclosure A. Krishnakumar: Employee; Self; Wellthy Therapeutics. V. Kumar: None. B.D. Saboo: None. V. Khatry: None. S. Joshi: Consultant; Self; Wellthy Therapeutics. R.R. Adhikary: Employee; Self; Wellthy Therapeutics. S. Kolwankar: Employee; Self; Wellthy Therapeutics. V. Mattoo: None.
Background: Diabetes self-management education and support (DSMES) is integral towards maintaining continuity of care between physician visits especially for patients on insulin therapy to facilitate healthy coping. The present study explores the usage patterns and real-world effectiveness of the Wellthy CARE™ digital therapeutic (WDTx) platform in achieving glycemic control among patients with type 2 diabetes mellitus (T2DM) on insulin therapy. Methods: The WDTx platform consists of a smartphone application with a 52-week program to provide DSMES through self-monitoring of blood glucose, access to evidence-based content regarding insulin usage and remote guidance by a health coach to enable lifestyle modifications and healthy coping. All app interactions were analyzed at baseline and during the program to determine factors driving patient engagement and clinical outcomes. Results: Study participants (n=106) had a mean age of 51.4 years (SD 14.0 years) and consisted of 39 females (36.8%). Overall, a significant mean decrease in average blood sugar (ABS) by 29.9 mg/dl (95%CI 16.6-43.3 mg/dl, P<0.001) was observed with a 31.9% reduction in proportion of hypoglycemia logs and an average of 6.1 app interactions per patient per week on the platform thus proving continuity of care provided through WDTx. Users in the highest tertile for early app interactions (within week 1) demonstrated a significant mean decrease in ABS by 30.8 mg/dl (95%CI 7.5-54.0 mg/dl, P<0.01) while no significant change was seen in the corresponding lowest tertile. Over the entire program, users in the tertile with highest app engagement showed a significant mean decrease in ABS of 27.4 mg/dl (95%CI 8.8-46.1 mg/dl, P<0.01) as compared to no significant change in the lowest tertile. Conclusion: This study thus demonstrates the effectiveness of the WDTx platform to impart critical DSMES, maintain continuity of care and improve clinical outcomes in patients with T2DM on insulin therapy. Disclosure R. R. Adhikary: Employee; Self; Wellthy Therapeutics Pvt Ltd. S. Kolwankar: Employee; Self; Wellthy Therapeutics Pvt Ltd. R. Verma: Consultant; Self; Wellthy Therapeutics Pvt Ltd. J. Bhatt: Employee; Self; Wellthy Therapeutics Pvt Ltd. K. L. Pakhale: None. R. Sahay: Advisory Panel; Self; Cipla Inc., USV Private Limited, Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk Pharma Ltd.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.